Hi OHDSI community,
We are a Danish research group currently working on vocabulary mapping of several major Danish Health Data databases to the OMOP CDM, and have a question concerning drug and therapy mappings.
We are mapping drugs directly to RxNorm, wherever possible, and thankfully, the majority of the database can follow OHDSI mapping guidelines nicely. However, our database also has concepts that are higher up in the hierarchy, e.g. not a specific drug ingredient, but a group of ingredients. While this is a problem in itself for the medical interpretation, I am wondering how this will affect analysis, e.g. in prediction models.
Example: In treatments with biological medications, a patient can get the drug ‘Infliximab’, but it can also be registered as ‘Biological therapy’. A biological therapy can be found only as a procedure code. I am wondering how this will affect analysis at a later stage, as procedure codes obviously will not show up in the drug era table.
The problem is similar for concepts like ‘TNF-alpha inhibitors’, ‘Hormone treatment’, ‘Steroid treatment’, ‘Antacids’, ‘Treatment with VEG-F antibody’… (the list goes on) that are only available as procedure codes (or classification, which we obviously cannot map to).
I was wondering if anyone has thoughts on this, how to remedy this in mapping the vocabulary or analysis, or whether there are any plans to create higher-up concepts that can be used in drug studies.
I looked through the forums, and I don’t think this question has been posted before, but if I overlooked it, my sincere apologies and please send me a link to the thread.